Kawasaki Disease Clinical Trial
Official title:
Efficacy of Primary Treatment With Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease: a Multicenter, Open-label, Blinded-end Randomized Controlled Study.
NCT number | NCT04535518 |
Other study ID # | KD-4-01 |
Secondary ID | |
Status | Withdrawn |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | October 2020 |
Est. completion date | September 2022 |
Verified date | March 2021 |
Source | Children's Hospital of Fudan University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the efficacy of the addition of infliximab to conventional initial treatment (intravenous immunoglobulin [IVIG] plus aspirin) in early regression of coronary artery lesion in patients with Kawasaki disease (KD).
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | September 2022 |
Est. primary completion date | September 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Month to 14 Years |
Eligibility | Inclusion Criteria: - Meeting diagnostic criteria for KD released by American Heart Association (AHA) in 2017, including complete KD (also sometimes referred to as typical or classic KD) and incomplete KD ((also sometimes referred to as atypical KD); - Diagnosed within 14 days of illness (including the 14th day, considering the first day of illness as the first day of fever); - Not treated with IVIG or other treatments for KD yet; - Z score of any coronary artery of LMCA, LAD, LCX, the proximal and middle segment of RCA = 2 calculated based on the height, weight and coronary artery diameter measured by echocardiography; - Aged between one month and 14 years. Exclusion Criteria: - Receiving steroids or other immunosuppressive agents in the previous 30 days; - With a previous history of KD; - Afebrile and all the inflammation indicators (including white blood cell count, CRP, and erythrocyte sedimentation) become normal before enrolment; - With suspected infectious diseases including tuberculosis, sepsis, septic meningitis, peritonitis, bacterial pneumonia, varicella, influenza, EBV infection, etc; - With serious immune diseases such as immunodeficiency or chromosomal abnormalities; - Unable to be followed up for at least 1 year. |
Country | Name | City | State |
---|---|---|---|
China | Children's Hospital of Fudan University | Shanghai | |
China | Shanghai 10th People's Hospital | Shanghai | |
China | Shanghai Children's Hospital | Shanghai | |
China | Shanghai Children's Medical Center | Shanghai | |
China | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Children's Hospital of Fudan University | Shanghai 10th People's Hospital, Shanghai Children's Hospital, Shanghai Children's Medical Center, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
China,
Dallaire F, Dahdah N. New equations and a critical appraisal of coronary artery Z scores in healthy children. J Am Soc Echocardiogr. 2011 Jan;24(1):60-74. doi: 10.1016/j.echo.2010.10.004. Epub 2010 Nov 13. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of the regression of coronary artery lesion (CAL) at one month of illness | The regression of CAL is defined as z < 2 of all coronary arteries of LMCA, LAD, LCX, and the proximal and middle segment of the RCA.Two-dimensional echocardiography will be performed to evaluate CAL at 1 month of illness. The measurement of each patient included the diameter of the left main coronary artery (LMCA), the left anterior descending artery (LAD), the left circumflex coronary artery (LCX), and the proximal and middle segments of the right coronary artery (RCA). Z score of each coronary artery will be calculated (Journal of the American Society of Echocardiography, 2011, 24(1):60-74). | at one month of illness | |
Secondary | Percentage of the need for additional treatment | Participants who have recurrent or persistent fever (axillary temperature =37.5°C or rectal temperature =38°C) after 36 hours of completion of initial IVIG infusion will be given additional treatment, including a second dose of IVIG (2 g/kg), or a high dose of methylprednisolone (10 to 30 mg/kg per day), or other immunosuppressive agents such as ciclosporin and cyclophosphamide, or a combination with two or more drugs, or even more aggressive treatment such as plasmapheresis, depending on patients'condition and physicians' experience. Axillary temperature (or rectal temperature) will be measured every 6 hours a day during hospitalization. | from admission to discharge (about 2 weeks of illness) | |
Secondary | z scores of LMCA throughout the study period | This is a repeated measurement. Z score will be calculated based on the height, weight and coronary artery diameter (Journal of the American Society of Echocardiography, 2011, 24(1): 60-74.). The internal diameter of LMCA will be measured by echocardiography at least seven time points: at enrollment, at 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of illness. | from admission to 12 months of illness | |
Secondary | z scores of LAD throughout the study period | This is a repeated measurement. Z score will be calculated based on the height, weight and coronary artery diameter (Journal of the American Society of Echocardiography, 2011, 24(1): 60-74.). The internal diameter of LAD will be measured by echocardiography at least seven time points: at enrollment, at 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of illness. | from admission to 12 months of illness | |
Secondary | z scores of LCX throughout the study period | This is a repeated measurement. Z score will be calculated based on the height, weight and coronary artery diameter (Journal of the American Society of Echocardiography, 2011, 24(1): 60-74.). The internal diameter of LCX will be measured by echocardiography at least seven time points: at enrollment, at 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of illness. | from admission to 12 months of illness | |
Secondary | z scores of the proximal segment of RCA throughout the study period | This is a repeated measurement. Z score will be calculated based on the height, weight and coronary artery diameter (Journal of the American Society of Echocardiography, 2011, 24(1): 60-74.). The internal diameter of the proximal segment of RCA will be measured by echocardiography at least seven time points: at enrollment, at 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of illness. | from admission to 12 months of illness | |
Secondary | z scores of the middle segment of RCA throughout the study period | This is a repeated measurement. Z score will be calculated based on the height, weight and coronary artery diameter (Journal of the American Society of Echocardiography, 2011, 24(1): 60-74.). The internal diameter of the middle segment of RCA will be measured by echocardiography at least seven time points: at enrollment, at 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of illness. | from admission to 12 months of illness | |
Secondary | Duration of fever (hours) after initiation of initial IVIG infusion | Participants with an axillary temperature <37.5? (or rectal temperature <38?) for more than 24 hours are considered afebrile. Axillary temperature (or rectal temperature) will be measured every 6 hours a day during hospitalization. Record the time of the initiation of IVIG infusion and the time of the body temperature first becoming normal. | from initiation of initial IVIG infusion to the first record of being afebrile (defined as an axillary temperature <37.5 for more than 24 hours) | |
Secondary | Change in serum C-reactive protein (CRP) concentration | CRP level is measured before initial IVIG infusion and 72 hours after completion of initial IVIG infusion.Change would be described by difference. | from admission to 72 hours after completion of initial IVIG infusion | |
Secondary | Number of patients with serious adverse events | This is a composite outcome, including death, hypertension (defined as the blood pressure (BP) =90th percentile for age and height or = 120/80 mmHg in the children younger than 13, and = 120/80 mmHg in children = 13 years), severe infection (such as septicopyemia, pulmonary infection and urinary system infection), allergic reactions, heart failure, thrombosis, etc. | from admission to 12 months of illness | |
Secondary | Percentage of the regression of coronary artery lesion (CAL) at 3 months of illness | The regression of CAL is defined as the z < 2 of all coronary arteries of LMCA, LAD, LCX, and the proximal and middle segment of the RCA. | at 3 months of illness | |
Secondary | Percentage of the regression of coronary artery lesion (CAL) at 6 months of illness | The regression of CAL is defined as the z < 2 of all coronary arteries of LMCA, LAD, LCX, and the proximal and middle segment of the RCA. | at 6 months of illness | |
Secondary | Percentage of the regression of coronary artery lesion (CAL) at 9 months of illness | The regression of CAL is defined as the z < 2 of all coronary arteries of LMCA, LAD, LCX, and the proximal and middle segment of the RCA. | at 9 months of illness | |
Secondary | Percentage of the regression of coronary artery lesion (CAL) at 12 months of illness | The regression of CAL is defined as the z < 2 of all coronary arteries of LMCA, LAD, LCX, and the proximal and middle segment of the RCA. | at 12 months of illness |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05911386 -
Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases
|
||
Recruiting |
NCT02951234 -
A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease
|
N/A | |
Active, not recruiting |
NCT02853266 -
Measurement of Antibodies in Adults With a History of Kawasaki Disease
|
N/A | |
Active, not recruiting |
NCT04747847 -
Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease
|
Early Phase 1 | |
Recruiting |
NCT01917721 -
Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease
|
Phase 2 | |
Recruiting |
NCT04656184 -
A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment
|
Phase 3 | |
Recruiting |
NCT03200561 -
A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)
|
Phase 3 | |
Completed |
NCT01440075 -
Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease
|
N/A | |
Completed |
NCT02179853 -
Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02980263 -
Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease
|
Phase 2 | |
Enrolling by invitation |
NCT02359643 -
Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease
|
N/A | |
Recruiting |
NCT04278404 -
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
|
||
Completed |
NCT00841789 -
A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease
|
Phase 2 | |
Completed |
NCT00760435 -
Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease
|
Phase 3 | |
Not yet recruiting |
NCT05643651 -
Rivaroxaban for Children With Giant Coronary Artery Aneurysms After Kawasaki Disease
|
Phase 4 | |
Recruiting |
NCT02114099 -
Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease
|
Phase 2 | |
Not yet recruiting |
NCT05091229 -
A Blood Test to Diagnose Kawasaki Disease
|
||
Completed |
NCT01431105 -
Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities
|
Phase 1/Phase 2 | |
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Recruiting |
NCT06305611 -
European and North Indian Cohort of KaWasaki dIsease
|